Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent

Circulation

Volumn 104, Issue 25, 2001, Pages 3116-3120

  Lee, Yong Kyu ^a   Nam, Jong Hee ^b   Shin, Ho Chul ^c   Byun, Youngro ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Conjugates; Deoxycholic acid; Drugs; Heparin

Indexed keywords

DEOXYCHOLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; POLYSACCHARIDE;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CONJUGATE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; LUNG EMBOLISM; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

EID: 0035910004     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc5001.100627     Document Type: Article

References (23)

1. Heparin: A generalized view of its anticoagulant action
2. The anticoagulant activation of antithrombin by heparin
3. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism
4. Effect of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis
5. Heparins: Anionic polyelectrolyte drugs
6. The effect of physical barriers and properties on the oral absorption of particulates
7. New heparin complexes active by intestinal absorption, I: Multiple ion pairs with basic organic compounds
8. Intraduodenal absorption of the new UF-heparin salt ITF 1057 in the conscious dog
9. An evaluation of the oral administration of commercial and fractionated heparin samples in rats
10. Effects of acidity, cations and alcoholic fractionation on absorption of heparin from gastrointestinal tract
11. Intestinal absorption of heparin facilitated by sulphated or sulfonated surfactants
12. Oral delivery of antico-agulant doses of heparin: A randomized, double-blind, controlled study in humans
13. The development of delivery agents that facilitate the oral absorption of macromolecular drugs
14. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis
15. Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation
16. Oral delivery of new heparin derivatives in rats
17. Low molecular weight heparin
18. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate: Pharmacological considerations
19. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat
20. Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP
21. Development of oral heparin therapy for prophylaxis and treatment of deep vein thrombosis
22. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
23. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various